Age-Related Changes in Growth Hormone Signaling: Pathophysiology, Clinical Implications, and Emerging Therapeutic Insights

Abstract

Age-related changes in growth hormone (GH) signaling represent a pivotal aspect of the endocrine aging process, profoundly influencing body composition, metabolic health, and overall physiologic resilience. This review synthesizes current evidence from molecular, clinical, and epidemiological studies to delineate the mechanisms underlying altered GH dynamics with aging, the epidemiological and clinical burden associated with declining GH activity, and the implications for diagnostics and therapeutic strategies. Emphasis is placed on the integration of mechanistic insights with evidence-based management and guideline-directed recommendations to provide a comprehensive reference for clinicians and healthcare professionals.

Introduction

Growth hormone exerts essential anabolic, metabolic, and regenerative actions across the lifespan. However, aging is characterized by a progressive decline in endogenous GH secretion, termed somatopause, which contributes to the phenotypic hallmarks of aging such as sarcopenia, visceral adiposity, and metabolic dysregulation. Understanding the nuances of GH signaling alterations with age is crucial for clinicians managing age-related morbidity and for guiding the implementation of targeted interventions. This review explores the epidemiology, mechanistic underpinnings, clinical manifestations, diagnostic approaches, and emerging therapies related to the age-dependent attenuation of GH function.

Epidemiology / Disease Burden

The gradual reduction in GH secretion begins in early adulthood, with serum GH and insulin-like growth factor-1 (IGF-1) levels decreasing by approximately 14-15% per decade. This decline affects both sexes, although the rate and degree may vary due to factors such as sex steroids, body composition, and comorbidities. Epidemiological data link low GH/IGF-1 states in older adults to increased prevalence of metabolic syndrome, decreased bone mineral density, heightened cardiovascular risk, and impaired quality of life. The burden is further accentuated by an aging global population, highlighting the need for improved recognition and management of GH deficiency syndromes in the elderly.

Pathophysiology

GH secretion is governed by a complex neuroendocrine axis involving hypothalamic growth hormone-releasing hormone (GHRH), somatostatin, and pituitary somatotroph responsiveness. With advancing age, there is diminished hypothalamic GHRH output, increased somatostatinergic tone, and reduced pituitary sensitivity to secretagogues. Peripheral GH resistance is also observed, attributed to post-receptor signaling defects and increased levels of inhibitory cytokines. The resultant attenuation in IGF-1 synthesis impairs anabolic pathways while permitting catabolic processes to dominate, manifesting as sarcopenia and metabolic deterioration. Emerging research implicates alterations in GH receptor isoform expression, changes in signal transduction (JAK2/STAT5), and increased proteolytic cleavage of GH-binding proteins as contributory mechanisms to the age-related decline in GH efficacy.

Risk Factors

Key risk factors for accelerated age-related decline in GH signaling include obesity, insulin resistance, chronic systemic inflammation, sedentary lifestyle, and the presence of comorbidities such as type 2 diabetes mellitus and cardiovascular disease. Genetic predisposition, exposure to glucocorticoids, and chronic psychological stress further exacerbate hypothalamic-pituitary dysregulation. Notably, the interplay between visceral adiposity and GH suppression forms a vicious cycle, whereby increased adiposity reduces GH output, perpetuating further fat accumulation and metabolic risk.

Clinical Features

Clinically, the consequences of diminished GH activity in older adults are multifaceted. Key features include reduced lean body mass, increased central adiposity, osteopenia or osteoporosis, decreased exercise capacity, and impaired lipid and glucose homeostasis. Patients may also exhibit diminished skin thickness, slow wound healing, and reduced immune competence. Psychological manifestations, such as reduced quality of life, fatigue, and cognitive decline, are commonly reported but often underrecognized. The overlap with normal aging requires a nuanced clinical approach to distinguish pathological GH deficiency from physiological aging.

Diagnosis

Diagnosis of GH deficiency in the elderly is challenging due to the physiological decline in GH/IGF-1 with age and the lack of age-adjusted reference ranges. Standard assessment involves measurement of IGF-1 levels and dynamic stimulation tests (e.g., insulin tolerance test, GHRH-arginine test), with careful consideration of comorbidities and confounding factors. Novel biomarkers and imaging modalities, such as pituitary MRI, may aid in differential diagnosis, but clinical judgement remains paramount. Current guidelines advocate individualized diagnostic criteria, emphasizing the integration of biochemical, radiological, and clinical data.

Treatment & Management

The therapeutic management of age-related GH deficiency is controversial and must balance potential anabolic benefits against the risk of adverse effects. Recombinant human GH therapy can improve body composition, bone density, and metabolic parameters in selected patients, but is associated with side effects including arthralgia, edema, insulin resistance, and increased risk of neoplasia. Lifestyle modifications especially resistance exercise, dietary interventions, and optimization of comorbidities are foundational and demonstrate robust efficacy in mitigating GH decline consequences. Pharmacologic agents targeting the GH-IGF-1 axis, such as GHRH analogs and GH secretagogues, are under investigation and may offer alternative strategies with improved safety profiles.

Recent Advances / Emerging Therapies

Recent advances in the understanding of GH signaling have spurred the development of novel agents, including oral GH secretagogues (e.g., ibutamoren), selective GH receptor modulators, and IGF-1 mimetics. Preclinical and early clinical studies suggest these therapies may restore physiological GH pulsatility and downstream anabolic effects with a more favorable safety profile than exogenous GH. Advances in gene therapy and regenerative medicine also hold promise for targeted restoration of hypothalamic-pituitary function. Ongoing trials are evaluating the long-term outcomes and risk-benefit profile of these interventions in elderly populations.

Guideline Recommendations

Consensus guidelines from endocrine societies recommend against routine GH supplementation in otherwise healthy older adults, citing insufficient evidence of benefit and potential for harm. In patients with documented organic GH deficiency and significant clinical impairment unresponsive to conventional measures, individualized GH therapy may be considered with close monitoring for metabolic and neoplastic complications. Emphasis is placed on shared decision-making, regular re-evaluation, and prioritization of non-pharmacologic interventions as first-line therapy.

Conclusion

Age-related changes in GH signaling constitute a clinically significant yet underappreciated aspect of endocrine aging, with implications for metabolic health, physical function, and quality of life. Advances in pathophysiological understanding and diagnostic precision are enabling more nuanced identification and management of affected individuals. Future research should focus on optimizing risk stratification, developing safer therapeutics, and elucidating the long-term clinical outcomes of targeted interventions. For clinicians, a personalized, evidence-based approach that integrates lifestyle, pharmacologic, and emerging modalities offers the greatest promise for mitigating the health burden of age-related GH decline.